Dr. Taral Patel MD
Oncologist, MID-OHIO ONCOLOGY & HEMOTOLOGY INC
Member of the Healthcare Council
Council Member Biography
Taral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer, lymphoma, and growth factor. He has been on the advisory board for several drug companies including Amgen, Novartis, Lilly, Genetech, and Aventis. (This is me - Update Profile)
Employment History
- 1999 - Unspecified
- Oncologist, MID-OHIO ONCOLOGY & HEMOTOLOGY INC
GLG NewsSM Analyses by Taral Patel(?)
Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
-
February 19, 2008
In Second Trial, Avastin Is Found Effective in Treating Breast Cancer | www.nytimes.com
New data with low and high dose of Avastin with Taxoter
-
improve Overall survival in prostate cancer
February 19, 2008
Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival | www.pipelinereview.com
esults showed that PROVENGE patients experienced improved survival if they received more cells across the three doses of PROVENGE (higher cumulative TNC count (p=0.019)) or higher cumulative CD54 upregulation values (p=0.009). The effect on survival for TNCs appeared to reflect in part the patients' baseline prognostic factors. However, the CD54 upregulation ratio appeared to be an independent predictor of survival in patients who received PROVENGE, as the correlation remained strong even after adjusting for baseline prognostic factors (p=0.022). Data is very impressive. This may lead FDA approval in prostate cancer in next 3-6 months.
-
December 7, 2007
F.D.A. Criticizes Avastin Use for Breast Cancer | www.nytimes.com
“On face value the data look very good,” said Buzdar, who voted with the slim (5-4) majority against the drug. In the study that was the basis of Genentech’s application, Avastin appeared to slow the progress of the disease. advanced breast cancer who had already tried other drugs. He said he’s never used Avastin to treat breast cancer, but he knows other doctors do, despite the lack of FDA’s blessing. “Physicians always want to do something for the patient,” he said. But he believes the panel’s vote “will make them think twice” before they try Avastin for breast cancer. “This drug is a good drug,” Buzdar added. “It does work in a number of other cancers where it not only prolongs control of the disease but it keeps more patients alive. In breast cancer, it has not panned out.”
-
August 29, 2007
New Medicare Regulations Adopted To Reduce Certain Hospital Infections And Medical Errors | www.medicalnewstoday.com
CMS is doing right thing. This will aviod pt fall and bedsore during hospitalzation
-
August 9, 2007
Bristol-Myers Squibb and Imclone Systems Significantly Expand ERBITUX Clinical Development Program | www.pipelinereview.com
The comprehensive clinical program will supplement the significant body of clinical data existing for ERBITUX in colorectal and head and neck cancers by exploring the use of ERBITUX in additional tumor types including brain, breast, bladder, gastric, lung, pancreas and prostate
Leading institutions connect with Taral Patel through GLG
GLG Study Groups with Taral Patel(?)
| Study Group Name | No. Members |
|---|---|
| Experts in the Leisure & Lodging Council | 4887 |
| Experts in the Automotive Council | 3422 |
| Oncologists (US) | 2241 |
| Generic Drug Economic Experts | 766 |
| Hematologists and Oncologists in Private Practice (US) | 462 |
GLG Live Meetings with Taral Patel(?)
Taral Patel has not participated in any GLG Live Meetings.